SAN FRANCISCO, Calif.—Verana Health and the American Academy of Ophthalmology have announced the Verana Research Network, an IRIS Registry (Intelligent Research in Sight) initiative intended to help advance data-driven clinical research and care. The network consists of academic medical centers (AMCs) and ophthalmology practices joining together to utilize IRIS Registry data and Verana Health capabilities to help improve patients' access to, and streamline health care providers' execution of clinical trials. Founding participating practices and institutions are experienced in conducting clinical trials, committed to advancing data-driven clinical research, and regarded by the Academy as experts in their field.

The Verana Research Network includes 10 founding sites and is now inviting additional practices across the IRIS Registry to participate.

"The American Academy of Ophthalmology continues to look for ways to extend the value of the IRIS Registry to advance patient care and outcomes," said Rahul Khurana, MD, a clinical researcher and practicing ophthalmologist at Northern California Retina Vitreous Associates, a Verana Research Network founding site. "With the Verana Research Network, the Academy and Verana Health are helping clinical trial sites run data-driven trials that can potentially bring therapeutic innovations to patients faster."

Established by the American Academy of Ophthalmology in 2014, the IRIS Registry is one of the largest specialty society clinical data registries in all of medicine. Verana Health is the Academy's exclusive end-to-end data curation and analytics partner for the IRIS Registry. This enables Verana Health to securely help practices participating in the IRIS Registry to use data-driven approaches to help recruit patients likely to meet clinical trials requirements.

The Verana Research Network helps participating institutions and practices increase access to clinical trials, accelerate trial recruitment and advance ophthalmic clinical research.

"Our members are always seeking ways to provide the most up-to-date and the highest quality care to their patients and this joint initiative between the Academy and Verana Health is another example of how the IRIS Registry supports innovations that will improve this care," said American Academy of Ophthalmology chief executive officer Stephen D. McLeod, MD. "The Verana Research Network will help speed access for ophthalmology patients to participate in clinical trials that develop impactful and effective therapies to help protect patients' sight."

"Our vision is to bring together practices and data in a trusted, secure fashion, built on the cornerstone of quality, curated, de-identified real-world data from our specialty society partners," said Verana Health chief executive officer Sujay Jadhav. "The Verana Research Network—and our partnership with the American Academy of Ophthalmology—is helping advance ophthalmic research and accelerate treatments for patients."